Clinical Trial Update: Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors [NA]

View source ↗

Summary

The trial update provides extensive cardiovascular characterization and follow-up data for patients receiving immune checkpoint inhibitors in cancer, highlighti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cemiplimab (cemiplimab)
• Durvalumab (durvalumab)
• Immune checkpoint inhibitors (class)
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Algemeen Ziekenhuis Maria Middelares | Conditions: Cancer, Immune-related Adverse Event | NA | Status: TERMINATED